Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgrastim randomized pilot study of CD34+ stem cells in the splanchnic district in cirrhotic patients
2009-014721-16Phase 2Terminated
- Sponsor
- UPMC ISMETT
- Start
- Jan 2010
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of filgrastim in Cirrhosis (2 arms), sponsored by UPMC ISMETT. Primary endpoints: Predominant production of CD34+ stem cells in the splanchnic district and Hepatic homing of CD34+ stem cells. Started Jan 2010; status: terminated.
02
Drugs
filgrastim
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on 2009-014721-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014721-16.